{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:51:54Z","timestamp":1790844714698,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["003397D122"],"award-info":[{"award-number":["003397D122"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CHEN21F0"],"award-info":[{"award-number":["CHEN21F0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2023-0217"],"award-info":[{"award-number":["2023-0217"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015521","name":"Stanford Maternal and Child Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016616","name":"Cystic Fibrosis Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016616","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Thomas Merigan Scholarship"},{"name":"Center for Bacteriophage Biology and Therapy"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI12492093"],"award-info":[{"award-number":["R01AI12492093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stanford Spark"},{"name":"The Emerson Collective"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00408-024-00700-7","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T19:01:41Z","timestamp":1716318101000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Phage Therapy for Respiratory Infections: Opportunities and Challenges"],"prefix":"10.1007","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-3556","authenticated-orcid":false,"given":"Arya","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Echterhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-3173","authenticated-orcid":false,"given":"Jonathan L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-9448","authenticated-orcid":false,"given":"Paul L.","family":"Bollyky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"The Lancet"},{"key":"700_CR2","unstructured":"The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 17 Nov 2023"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jcf.2022.10.005","volume":"21","author":"P Drevinek","year":"2022","unstructured":"Drevinek P, Canton R, Johansen HK et al (2022) New concepts in antimicrobial resistance in cystic fibrosis respiratory infections. J Cyst Fibros 21:937\u2013945. https:\/\/doi.org\/10.1016\/j.jcf.2022.10.005","journal-title":"J Cyst Fibros"},{"key":"700_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2021.2000957","author":"D Smith","year":"2021","unstructured":"Smith D, Gill A, Hall L (2021) Prevalence, pattern, risks factors and consequences of antibiotic resistance in COPD: a systematic review. J Chronic Obstr Pulm Dis. https:\/\/doi.org\/10.1080\/15412555.2021.2000957","journal-title":"J Chronic Obstr Pulm Dis"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.21037\/jtd.2018.05.204","volume":"10","author":"M Nosotti","year":"2018","unstructured":"Nosotti M, Tarsia P, Morlacchi LC (2018) Infections after lung transplantation. J Thorac Dis 10:3849\u20133868. https:\/\/doi.org\/10.21037\/jtd.2018.05.204","journal-title":"J Thorac Dis"},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/antibiotics10030326","volume":"10","author":"R Inchingolo","year":"2021","unstructured":"Inchingolo R, Pierandrei C, Montemurro G et al (2021) Antimicrobial resistance in common respiratory pathogens of chronic bronchiectasis patients: a literature review. Antibiot (Basel) 10:326. https:\/\/doi.org\/10.3390\/antibiotics10030326","journal-title":"Antibiot (Basel)"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1055\/s-0039-1697975","volume":"40","author":"CH Goss","year":"2019","unstructured":"Goss CH (2019) Acute pulmonary exacerbation in cystic fibrosis. Semin Respir Crit Care Med 40:792\u2013803. https:\/\/doi.org\/10.1055\/s-0039-1697975","journal-title":"Semin Respir Crit Care Med"},{"key":"700_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA, Mogayzel PJ, Robinson KA et al (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802\u2013808. https:\/\/doi.org\/10.1164\/rccm.200812-1845PP","journal-title":"Am J Respir Crit Care Med"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","volume":"182","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Bittner RCL, Rosenfeld M et al (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182:627\u2013632. https:\/\/doi.org\/10.1164\/rccm.200909-1421OC","journal-title":"Am J Respir Crit Care Med"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM et al (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340:23\u201330. https:\/\/doi.org\/10.1056\/NEJM199901073400104","journal-title":"N Engl J Med"},{"key":"700_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/antibiotics10030338","volume":"10","author":"G Taccetti","year":"2021","unstructured":"Taccetti G, Francalanci M, Pizzamiglio G et al (2021) Cystic fibrosis: recent insights INTO inhaled antibiotic treatment and future perspectives. Antibiot (Basel) 10:338. https:\/\/doi.org\/10.3390\/antibiotics10030338","journal-title":"Antibiot (Basel)"},{"key":"700_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub5","author":"SC Langton Hewer","year":"2017","unstructured":"Langton Hewer SC, Smyth AR (2017) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004197.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"106283","DOI":"10.1016\/j.rmed.2020.106283","volume":"176","author":"S Sangiovanni","year":"2021","unstructured":"Sangiovanni S, Morales EI, Fern\u00e1ndez-Trujillo L (2021) Inhaled tobramycin for chronic infection with Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respir Med 176:106283. https:\/\/doi.org\/10.1016\/j.rmed.2020.106283","journal-title":"Respir Med"},{"key":"700_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","volume":"25","author":"KE Kortright","year":"2019","unstructured":"Kortright KE, Chan BK, Koff JL, Turner PE (2019) Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25:219\u2013232. https:\/\/doi.org\/10.1016\/j.chom.2019.01.014","journal-title":"Cell Host Microbe"},{"key":"700_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4161\/bact.20757","volume":"2","author":"WC Summers","year":"2012","unstructured":"Summers WC (2012) The strange history of phage therapy. Bacteriophage 2:130\u2013133. https:\/\/doi.org\/10.4161\/bact.20757","journal-title":"Bacteriophage"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.1934.72750490003007","volume":"103","author":"MD Eaton","year":"1934","unstructured":"Eaton MD, Bayne-Jones S (1934) Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. J Am Med Assoc 103:1769\u20131776. https:\/\/doi.org\/10.1001\/jama.1934.72750490003007","journal-title":"J Am Med Assoc"},{"key":"700_CR17","first-page":"77","volume":"45","author":"LM Marcuk","year":"1971","unstructured":"Marcuk LM, Nikiforov VN, Scerbak JF et al (1971) Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Org 45:77\u201383","journal-title":"Bull World Health Org"},{"key":"700_CR18","first-page":"723","volume":"42","author":"KA Monsur","year":"1970","unstructured":"Monsur KA, Rahman MA, Huq F et al (1970) Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bull World Health Org 42:723\u2013732","journal-title":"Bull World Health Org"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1099\/00221287-128-2-307","volume":"128","author":"HW Smith","year":"1982","unstructured":"Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307\u2013318. https:\/\/doi.org\/10.1099\/00221287-128-2-307","journal-title":"J Gen Microbiol"},{"key":"700_CR20","first-page":"569","volume":"35","author":"S Slopek","year":"1987","unstructured":"Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981\u20131986. Arch Immunol Ther Exp (Warsz) 35:569\u2013583","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/v11040343","volume":"11","author":"S McCallin","year":"2019","unstructured":"McCallin S, Sacher JC, Zheng J, Chan BK (2019) Current state of compassionate phage therapy. Viruses 11:343. https:\/\/doi.org\/10.3390\/v11040343","journal-title":"Viruses"},{"key":"700_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00954-17.10.1128\/aac.00954-17","author":"RT Schooley","year":"2017","unstructured":"Schooley RT, Biswas B, Gill JJ et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00954-17.10.1128\/aac.00954-17","journal-title":"Antimicrob Agents Chemother"},{"key":"700_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/emph\/eoy005","volume":"2018","author":"BK Chan","year":"2018","unstructured":"Chan BK, Turner PE, Kim S et al (2018) Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018:60\u201366. https:\/\/doi.org\/10.1093\/emph\/eoy005","journal-title":"Evol Med Public Health"},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM, Guerrero-Bustamante CA, Garlena RA et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus. Nat Med 25:730\u2013733. https:\/\/doi.org\/10.1038\/s41591-019-0437-z","journal-title":"Nat Med"},{"key":"700_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.28.23294728","author":"J-P Pirnay","year":"2023","unstructured":"Pirnay J-P, Djebara S, Steurs G et al (2023) Retrospective observational analysis of the first one hundred consecutive cases of personalized bacteriophage therapy of difficult-to-treat infections facilitated by a belgian consortium. medRxiv. https:\/\/doi.org\/10.1101\/2023.08.28.23294728","journal-title":"medRxiv"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","volume":"186","author":"SA Strathdee","year":"2023","unstructured":"Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT (2023) Phage therapy: from biological mechanisms to future directions. Cell 186:17\u201331. https:\/\/doi.org\/10.1016\/j.cell.2022.11.017","journal-title":"Cell"},{"key":"700_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0121-2022","author":"G Mitropoulou","year":"2022","unstructured":"Mitropoulou G, Koutsokera A, Csajka C et al (2022) Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations. Eur Respir Rev. https:\/\/doi.org\/10.1183\/16000617.0121-2022","journal-title":"Eur Respir Rev"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick RM, Smith BE, Cristinziano M et al (2023) Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis 76:103\u2013112. https:\/\/doi.org\/10.1093\/cid\/ciac453","journal-title":"Clin Infect Dis"},{"key":"700_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.23.22283996","author":"BK Chan","year":"2023","unstructured":"Chan BK, Stanley GL, Kortright KE et al (2023) Personalized inhaled bacteriophage therapy decreases multidrug-resistant pseudomonas aeruginosa. MedRxiv. https:\/\/doi.org\/10.1101\/2023.01.23.22283996","journal-title":"MedRxiv"},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","volume":"10","author":"N Wu","year":"2021","unstructured":"Wu N, Dai J, Guo M et al (2021) Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerg Microbes Infect 10:612\u2013618. https:\/\/doi.org\/10.1080\/22221751.2021.1902754","journal-title":"Emerg Microbes Infect"},{"key":"700_CR31","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","volume":"22","author":"S Uyttebroek","year":"2022","unstructured":"Uyttebroek S, Chen B, Onsea J et al (2022) Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis 22:e208\u2013e220. https:\/\/doi.org\/10.1016\/S1473-3099(21)00612-5","journal-title":"Lancet Infect Dis"},{"key":"700_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01462-20","author":"C Gu Liu","year":"2020","unstructured":"Gu Liu C, Green SI, Min L et al (2020) Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio. https:\/\/doi.org\/10.1128\/mbio.01462-20","journal-title":"MBio"},{"key":"700_CR33","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","volume":"2","author":"AM Comeau","year":"2007","unstructured":"Comeau AM, T\u00e9tart F, Trojet SN et al (2007) Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2:e799. https:\/\/doi.org\/10.1371\/journal.pone.0000799","journal-title":"PLoS ONE"},{"key":"700_CR34","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3390\/pharmaceutics14071425","volume":"14","author":"Q Chen","year":"2022","unstructured":"Chen Q, Dharmaraj T, Cai PC et al (2022) Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics. Pharmaceutics 14:1425. https:\/\/doi.org\/10.3390\/pharmaceutics14071425","journal-title":"Pharmaceutics"},{"key":"700_CR35","doi-asserted-by":"publisher","first-page":"e1011602","DOI":"10.1371\/journal.ppat.1011602","volume":"19","author":"J Bulssico","year":"2023","unstructured":"Bulssico J, PapukashvilI I, Espinosa L et al (2023) Phage-antibiotic synergy: cell filamentation is a key driver of successful phage predation. PLoS Pathog 19:e1011602. https:\/\/doi.org\/10.1371\/journal.ppat.1011602","journal-title":"PLoS Pathog"},{"key":"700_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1128\/jb.50.3.341-348.1945","volume":"50","author":"D Jones","year":"1945","unstructured":"Jones D (1945) The effect of antibiotic substances upon bacteriophage12. J Bacteriol 50:341\u2013348","journal-title":"J Bacteriol"},{"key":"700_CR37","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/ps\/83.12.1944","volume":"83","author":"WE Huff","year":"2004","unstructured":"Huff WE, Huff GR, Rath NC et al (2004) Therapeutic efficacy of bacteriophage and baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers1. Poult Sci 83:1944\u20131947. https:\/\/doi.org\/10.1093\/ps\/83.12.1944","journal-title":"Poult Sci"},{"key":"700_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/infdis\/jiw632","volume":"215","author":"F Oechslin","year":"2017","unstructured":"Oechslin F, Piccardi P, Mancini S et al (2017) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa Infection in endocarditis and reduces virulence. J Infect Dis 215:703\u2013712. https:\/\/doi.org\/10.1093\/infdis\/jiw632","journal-title":"J Infect Dis"},{"key":"700_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104045","author":"FLG Altamirano","year":"2022","unstructured":"Altamirano FLG, Kostoulias X, Subedi D et al (2022) Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104045","journal-title":"EBioMedicine"},{"key":"700_CR40","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick JA, Dedrick RM, Gray AL et al (2022) Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185:1860-1874.e12. https:\/\/doi.org\/10.1016\/j.cell.2022.04.024","journal-title":"Cell"},{"key":"700_CR41","doi-asserted-by":"publisher","first-page":"232470962311882","DOI":"10.1177\/23247096231188243","volume":"11","author":"A Hahn","year":"2023","unstructured":"Hahn A, Sami I, Chaney H et al (2023) Bacteriophage therapy for Pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis. J Investig Med High Impact Case Rep 11:23247096231188244. https:\/\/doi.org\/10.1177\/23247096231188243","journal-title":"J Investig Med High Impact Case Rep"},{"key":"700_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051017","volume":"7","author":"AE Kirby","year":"2012","unstructured":"Kirby AE (2012) Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 7:e51017. https:\/\/doi.org\/10.1371\/journal.pone.0051017","journal-title":"PLoS ONE"},{"key":"700_CR43","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.3390\/v6103778","volume":"6","author":"LB Coulter","year":"2014","unstructured":"Coulter LB, McLean RJC, Rohde RE, Aron GM (2014) Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6:3778\u20133786. https:\/\/doi.org\/10.3390\/v6103778","journal-title":"Viruses"},{"key":"700_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virusres.2017.07.015","volume":"240","author":"N Val\u00e9rio","year":"2017","unstructured":"Val\u00e9rio N, Oliveira C, Jesus V et al (2017) Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Res 240:8\u201317. https:\/\/doi.org\/10.1016\/j.virusres.2017.07.015","journal-title":"Virus Res"},{"key":"700_CR45","doi-asserted-by":"publisher","first-page":"26717","DOI":"10.1038\/srep26717","volume":"6","author":"BK Chan","year":"2016","unstructured":"Chan BK, Sistrom M, Wertz JE et al (2016) Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 6:26717. https:\/\/doi.org\/10.1038\/srep26717","journal-title":"Sci Rep"},{"key":"700_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41564-020-00830-7","volume":"6","author":"F Gordillo Altamirano","year":"2021","unstructured":"Gordillo Altamirano F, Forsyth JH, Patwa R et al (2021) Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol 6:157\u2013161. https:\/\/doi.org\/10.1038\/s41564-020-00830-7","journal-title":"Nat Microbiol"},{"key":"700_CR47","doi-asserted-by":"publisher","first-page":"e02085","DOI":"10.1128\/AEM.02085-18","volume":"84","author":"M Kim","year":"2018","unstructured":"Kim M, Jo Y, Hwang YJ et al (2018) Phage-antibiotic synergy via delayed lysis. Appl Environ Microbiol 84:e02085-e2118. https:\/\/doi.org\/10.1128\/AEM.02085-18","journal-title":"Appl Environ Microbiol"},{"key":"700_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/antibiotics8040182","volume":"8","author":"ST Abedon","year":"2019","unstructured":"Abedon ST (2019) Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage th erapy? Antibiotics 8:182. https:\/\/doi.org\/10.3390\/antibiotics8040182","journal-title":"Antibiotics"},{"key":"700_CR49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/antibiotics12030593","volume":"12","author":"I Martin","year":"2023","unstructured":"Martin I, Morales S, Alton EWFW, Davies JC (2023) Lytic bacteriophage is a promising adjunct to common antibiotics across cystic fibrosis clinical strains and culture models of Pseudomonas aeruginosa infection. Antibiot (Basel) 12:593. https:\/\/doi.org\/10.3390\/antibiotics12030593","journal-title":"Antibiot (Basel)"},{"key":"700_CR50","doi-asserted-by":"publisher","first-page":"13123","DOI":"10.1128\/jvi.76.24.13123-13124.2002","volume":"76","author":"RJH Payne","year":"2002","unstructured":"Payne RJH, Jansen VAA (2002) Evidence for a phage proliferation threshold? J Virol 76:13123\u201313124. https:\/\/doi.org\/10.1128\/jvi.76.24.13123-13124.2002","journal-title":"J Virol"},{"key":"700_CR51","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1126\/science.141.3585.1065","volume":"141","author":"TD Brock","year":"1963","unstructured":"Brock TD, Wooley SO (1963) Streptomycin as an antiviral agent: mode of action. Science 141:1065\u20131067. https:\/\/doi.org\/10.1126\/science.141.3585.1065","journal-title":"Science"},{"key":"700_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00783-22","author":"L Kever","year":"2022","unstructured":"Kever L, Hardy A, Luthe T et al (2022) Aminoglycoside antibiotics inhibit phage infection by blocking an early step of the infection cycle. MBio. https:\/\/doi.org\/10.1128\/mbio.00783-22","journal-title":"MBio"},{"key":"700_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1128\/JVI.39.3.855-860.1981","volume":"39","author":"JC Alonso","year":"1981","unstructured":"Alonso JC, Sarachu AN, Grau O (1981) DNA gyrase inhibitors block development of Bacillus subtilis bacteriophage SP01. J Virol 39:855\u2013860. https:\/\/doi.org\/10.1128\/JVI.39.3.855-860.1981","journal-title":"J Virol"},{"key":"700_CR54","doi-asserted-by":"publisher","first-page":"20160040","DOI":"10.1098\/rstb.2016.0040","volume":"372","author":"J Cairns","year":"2017","unstructured":"Cairns J, Becks L, Jalasvuori M, Hiltunen T (2017) Sublethal streptomycin concentrations and lytic bacteriophage together promote resistance evolution. Philoso Trans Royal Soc B Biol Sci 372:20160040. https:\/\/doi.org\/10.1098\/rstb.2016.0040","journal-title":"Philoso Trans Royal Soc B Biol Sci"},{"key":"700_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrmicro1793","volume":"6","author":"R Sorek","year":"2008","unstructured":"Sorek R, Kunin V, Hugenholtz P (2008) CRISPR \u2014 a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol 6:181\u2013186. https:\/\/doi.org\/10.1038\/nrmicro1793","journal-title":"Nat Rev Microbiol"},{"key":"700_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.chom.2021.11.014","volume":"30","author":"T Dimitriu","year":"2022","unstructured":"Dimitriu T, Kurilovich E, \u0141api\u0144ska U et al (2022) Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition. Cell Host Microbe 30:31-40.e5. https:\/\/doi.org\/10.1016\/j.chom.2021.11.014","journal-title":"Cell Host Microbe"},{"key":"700_CR57","doi-asserted-by":"publisher","first-page":"e2216084120","DOI":"10.1073\/pnas.2216084120","volume":"120","author":"BJ Pons","year":"2023","unstructured":"Pons BJ, Dimitriu T, Westra ER, van Houte S (2023) Antibiotics that affect translation can antagonize phage infectivity by interfering with the deployment of counter-defenses. Proc Natl Acad Sci 120:e2216084120. https:\/\/doi.org\/10.1073\/pnas.2216084120","journal-title":"Proc Natl Acad Sci"},{"key":"700_CR58","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1919888117","volume":"117","author":"AR Burmeister","year":"2020","unstructured":"Burmeister AR, Fortier A, Roush C et al (2020) Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci 117:11207\u201311216. https:\/\/doi.org\/10.1073\/pnas.1919888117","journal-title":"Proc Natl Acad Sci"},{"key":"700_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00127","author":"D Kumaran","year":"2018","unstructured":"Kumaran D, Taha M, Yi Q et al (2018) Does treatment order matter? investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2018.00127","journal-title":"Front Microbiol"},{"key":"700_CR60","doi-asserted-by":"publisher","first-page":"e106628","DOI":"10.1371\/journal.pone.0106628","volume":"9","author":"C Torres-Barcel\u00f3","year":"2014","unstructured":"Torres-Barcel\u00f3 C, Arias-S\u00e1nchez FI, Vasse M et al (2014) A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS ONE 9:e106628. https:\/\/doi.org\/10.1371\/journal.pone.0106628","journal-title":"PLoS ONE"},{"key":"700_CR61","doi-asserted-by":"publisher","first-page":"106951","DOI":"10.1016\/j.ijantimicag.2023.106951","volume":"62","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay S, Zhang P, To KKW et al (2023) Sequential treatment effects on phage\u2013antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 62:106951. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106951","journal-title":"Int J Antimicrob Agents"},{"key":"700_CR62","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00705-018-3811-0","volume":"163","author":"J Uchiyama","year":"2018","unstructured":"Uchiyama J, Shigehisa R, Nasukawa T et al (2018) Piperacillin and ceftazidime produce the strongest synergistic phage-antibiotic effect in Pseudomonas aeruginosa. Arch Virol 163:1941\u20131948. https:\/\/doi.org\/10.1007\/s00705-018-3811-0","journal-title":"Arch Virol"},{"key":"700_CR63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrd1008","volume":"2","author":"D Davies","year":"2003","unstructured":"Davies D (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114\u2013122. https:\/\/doi.org\/10.1038\/nrd1008","journal-title":"Nat Rev Drug Discov"},{"key":"700_CR64","doi-asserted-by":"publisher","first-page":"969326","DOI":"10.3389\/fcimb.2022.969326","volume":"12","author":"L Hall-Stoodley","year":"2022","unstructured":"Hall-Stoodley L, McCoy KS (2022) Biofilm aggregates and the host airway-microbial interface. Front Cell Infect Microbiol 12:969326. https:\/\/doi.org\/10.3389\/fcimb.2022.969326","journal-title":"Front Cell Infect Microbiol"},{"key":"700_CR65","doi-asserted-by":"publisher","first-page":"9691","DOI":"10.1038\/s41598-018-28009-5","volume":"8","author":"ES Gloag","year":"2018","unstructured":"Gloag ES, German GK, Stoodley P, Wozniak DJ (2018) Viscoelastic properties of Pseudomonas aeruginosa variant biofilms. Sci Rep 8:9691. https:\/\/doi.org\/10.1038\/s41598-018-28009-5","journal-title":"Sci Rep"},{"key":"700_CR66","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","volume":"37","author":"H Ceri","year":"1999","unstructured":"Ceri H, Olson ME, Stremick C et al (1999) The calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771\u20131776. https:\/\/doi.org\/10.1128\/JCM.37.6.1771-1776.1999","journal-title":"J Clin Microbiol"},{"key":"700_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.chom.2019.06.002","volume":"26","author":"J Yan","year":"2019","unstructured":"Yan J, Bassler BL (2019) Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms. Cell Host Microbe 26:15\u201321. https:\/\/doi.org\/10.1016\/j.chom.2019.06.002","journal-title":"Cell Host Microbe"},{"key":"700_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1078\/1438-4221-00196","volume":"292","author":"PS Stewart","year":"2002","unstructured":"Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107\u2013113. https:\/\/doi.org\/10.1078\/1438-4221-00196","journal-title":"Int J Med Microbiol"},{"key":"700_CR69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","volume":"8","author":"D Sharma","year":"2019","unstructured":"Sharma D, Misba L, Khan AU (2019) Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control 8:76. https:\/\/doi.org\/10.1186\/s13756-019-0533-3","journal-title":"Antimicrob Resist Infect Control"},{"key":"700_CR70","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jac\/22.5.667","volume":"22","author":"CA Gordon","year":"1988","unstructured":"Gordon CA, Hodges NA, Marriott C (1988) Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother 22:667\u2013674. https:\/\/doi.org\/10.1093\/jac\/22.5.667","journal-title":"J Antimicrob Chemother"},{"key":"700_CR71","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1128\/AEM.02636-13","volume":"79","author":"TK Wood","year":"2013","unstructured":"Wood TK, Knabel SJ, Kwan BW (2013) Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79:7116\u20137121. https:\/\/doi.org\/10.1128\/AEM.02636-13","journal-title":"Appl Environ Microbiol"},{"key":"700_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138920108785161604","volume":"9","author":"J Azeredo","year":"2008","unstructured":"Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261\u2013266. https:\/\/doi.org\/10.2174\/138920108785161604","journal-title":"Curr Pharm Biotechnol"},{"key":"700_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usad385","author":"CJ Kovacs","year":"2023","unstructured":"Kovacs CJ, Rapp EM, McKenzie SM et al (2023) Disruption of biofilm by bacteriophages in clinically relevant settings. Mil Med. https:\/\/doi.org\/10.1093\/milmed\/usad385","journal-title":"Mil Med"},{"key":"700_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389","author":"S Aslam","year":"2020","unstructured":"Aslam S, Lampley E, Wooten D et al (2020) Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant Bacterial infections at a single center in the United States. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofaa389","journal-title":"Open Forum Infect Dis"},{"key":"700_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","volume":"47","author":"N Law","year":"2019","unstructured":"Law N, Logan C, Yung G et al (2019) Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47:665\u2013668. https:\/\/doi.org\/10.1007\/s15010-019-01319-0","journal-title":"Infection"},{"key":"700_CR76","doi-asserted-by":"publisher","first-page":"2273567","DOI":"10.1080\/21505594.2023.2273567","volume":"14","author":"Z Guo","year":"2023","unstructured":"Guo Z, Liu M, Zhang D (2023) Potential of phage depolymerase for the treatment of bacterial biofilms. Virulence 14:2273567. https:\/\/doi.org\/10.1080\/21505594.2023.2273567","journal-title":"Virulence"},{"key":"700_CR77","doi-asserted-by":"publisher","first-page":"19033","DOI":"10.1038\/s41598-023-45313-x","volume":"13","author":"C Karthika","year":"2023","unstructured":"Karthika C, Malligarjunan N, Jothi R et al (2023) Two novel phages PSPa and APPa inhibit planktonic, sessile and persister populations of Pseudomonas aeruginosa, and mitigate its virulence in Zebrafish model. Sci Rep 13:19033. https:\/\/doi.org\/10.1038\/s41598-023-45313-x","journal-title":"Sci Rep"},{"key":"700_CR78","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ijantimicag.2018.09.006","volume":"52","author":"T Tkhilaishvili","year":"2018","unstructured":"Tkhilaishvili T, Lombardi L, Klatt A-B et al (2018) Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. Int J Antimicrob Agents 52:842\u2013853. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.006","journal-title":"Int J Antimicrob Agents"},{"key":"700_CR79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","volume":"21","author":"RYK Chang","year":"2019","unstructured":"Chang RYK, Das T, Manos J et al (2019) Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients. AAPS J 21:49. https:\/\/doi.org\/10.1208\/s12248-019-0315-0","journal-title":"AAPS J"},{"key":"700_CR80","doi-asserted-by":"publisher","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry WN, Concepci\u00f3n-Acevedo J, Park T et al (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE 12:e0168615. https:\/\/doi.org\/10.1371\/journal.pone.0168615","journal-title":"PLoS ONE"},{"key":"700_CR81","doi-asserted-by":"publisher","first-page":"e0209390","DOI":"10.1371\/journal.pone.0209390","volume":"14","author":"J Dickey","year":"2019","unstructured":"Dickey J, Perrot V (2019) Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLoS ONE 14:e0209390. https:\/\/doi.org\/10.1371\/journal.pone.0209390","journal-title":"PLoS ONE"},{"key":"700_CR82","doi-asserted-by":"publisher","first-page":"e04918","DOI":"10.1128\/spectrum.04918-22","volume":"11","author":"R Kebriaei","year":"2023","unstructured":"Kebriaei R, Lehman SM, Shah RM et al (2023) Optimization of phage-antibiotic combinations against Staphylococcus aureus biofilms. Microbiol Spectr 11:e04918-e4922. https:\/\/doi.org\/10.1128\/spectrum.04918-22","journal-title":"Microbiol Spectr"},{"key":"700_CR83","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1128\/AEM.67.6.2746-2753.2001","volume":"67","author":"GW Hanlon","year":"2001","unstructured":"Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ (2001) Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 67:2746\u20132753. https:\/\/doi.org\/10.1128\/AEM.67.6.2746-2753.2001","journal-title":"Appl Environ Microbiol"},{"key":"700_CR84","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1574-6976.1995.tb00179.x","volume":"16","author":"IW Sutherland","year":"1995","unstructured":"Sutherland IW (1995) Polysaccharide lyases. FEMS Microbiol Rev 16:323\u2013347. https:\/\/doi.org\/10.1111\/j.1574-6976.1995.tb00179.x","journal-title":"FEMS Microbiol Rev"},{"key":"700_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41564-017-0050-1","volume":"3","author":"L Vidakovic","year":"2018","unstructured":"Vidakovic L, Singh PK, Hartmann R et al (2018) Dynamic biofilm architecture confers individual and collective mechanisms of viral protection. Nat Microbiol 3:26\u201331. https:\/\/doi.org\/10.1038\/s41564-017-0050-1","journal-title":"Nat Microbiol"},{"key":"700_CR86","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65355","volume":"10","author":"MC Bond","year":"2021","unstructured":"Bond MC, Vidakovic L, Singh PK et al (2021) Matrix-trapped viruses can prevent invasion of bacterial biofilms by colonizing cells. Elife 10:e65355. https:\/\/doi.org\/10.7554\/eLife.65355","journal-title":"Elife"},{"key":"700_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01391","author":"D Bryan","year":"2016","unstructured":"Bryan D, El-Shibiny A, Hobbs Z et al (2016) Bacteriophage T4 infection of stationary Phase E. coli: life after log from a phage perspective. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2016.01391","journal-title":"Front Microbiol"},{"key":"700_CR88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/B978-0-12-394621-8.00019-4","volume":"82","author":"M \u0141o\u015b","year":"2012","unstructured":"\u0141o\u015b M, W\u0119grzyn G (2012) Pseudolysogeny. Adv Virus Res 82:339\u2013349. https:\/\/doi.org\/10.1016\/B978-0-12-394621-8.00019-4","journal-title":"Adv Virus Res"},{"key":"700_CR89","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1099\/00221287-144-8-2225","volume":"144","author":"S Ripp","year":"1998","unstructured":"Ripp S, Miller RV (1998) Dynamics of the pseudolysogenic response in slowly growing cells of Pseudomonas aeruginosa. Microbiol (Read) 144:2225\u20132232. https:\/\/doi.org\/10.1099\/00221287-144-8-2225","journal-title":"Microbiol (Read)"},{"key":"700_CR90","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41467-023-44157-3","volume":"15","author":"E Maffei","year":"2024","unstructured":"Maffei E, Woischnig A-K, Burkolter MR et al (2024) Phage paride can kill dormant, antibiotic-tolerant cells of Pseudomonas aeruginosa by direct lytic replication. Nat Commun 15:175. https:\/\/doi.org\/10.1038\/s41467-023-44157-3","journal-title":"Nat Commun"},{"key":"700_CR91","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1128\/JB.01651-09","volume":"192","author":"LR Mulcahy","year":"2010","unstructured":"Mulcahy LR, Burns JL, Lory S, Lewis K (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192:6191\u20136199. https:\/\/doi.org\/10.1128\/JB.01651-09","journal-title":"J Bacteriol"},{"key":"700_CR92","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.chom.2015.07.006","volume":"18","author":"P Jorth","year":"2015","unstructured":"Jorth P, Staudinger BJ, Wu X et al (2015) Regional isolation drives bacterial diversification within cystic fibrosis lungs. Cell Host Microbe 18:307\u2013319. https:\/\/doi.org\/10.1016\/j.chom.2015.07.006","journal-title":"Cell Host Microbe"},{"key":"700_CR93","doi-asserted-by":"publisher","first-page":"e1096995","DOI":"10.1080\/21597081.2015.1096995","volume":"6","author":"AC Mapes","year":"2016","unstructured":"Mapes AC, Trautner BW, Liao KS, Ramig RF (2016) Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage 6:e1096995. https:\/\/doi.org\/10.1080\/21597081.2015.1096995","journal-title":"Bacteriophage"},{"key":"700_CR94","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/s41467-023-39612-0","volume":"14","author":"J Du","year":"2023","unstructured":"Du J, Meile S, Baggenstos J et al (2023) Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors. Nat Commun 14:4337. https:\/\/doi.org\/10.1038\/s41467-023-39612-0","journal-title":"Nat Commun"},{"key":"700_CR95","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.7717\/peerj.590","volume":"2","author":"M Schmerer","year":"2014","unstructured":"Schmerer M, Molineux IJ, Bull JJ (2014) Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2:e590. https:\/\/doi.org\/10.7717\/peerj.590","journal-title":"PeerJ"},{"key":"700_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.613529","author":"MEK Haines","year":"2021","unstructured":"Haines MEK, Hodges FE, Nale JY et al (2021) Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2021.613529","journal-title":"Front Microbiol"},{"key":"700_CR97","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/antibiotics12121734","volume":"12","author":"F Zurabov","year":"2023","unstructured":"Zurabov F, Petrova M, Zurabov A et al (2023) Adaptive phage therapy for the prevention of recurrent nosocomial pneumonia: novel protocol description and case series. Antibiotics 12:1734. https:\/\/doi.org\/10.3390\/antibiotics12121734","journal-title":"Antibiotics"},{"key":"700_CR98","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ppul.25190","volume":"56","author":"BK Chan","year":"2021","unstructured":"Chan BK, Stanley G, Modak M et al (2021) Bacteriophage therapy for infections in CF. Pediatr Pulmonol 56:S4\u2013S9. https:\/\/doi.org\/10.1002\/ppul.25190","journal-title":"Pediatr Pulmonol"},{"key":"700_CR99","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317\u2013327. https:\/\/doi.org\/10.1038\/nrmicro2315","journal-title":"Nat Rev Microbiol"},{"key":"700_CR100","doi-asserted-by":"publisher","first-page":"101201","DOI":"10.1016\/j.coviro.2022.101201","volume":"53","author":"C Torres-Barcel\u00f3","year":"2022","unstructured":"Torres-Barcel\u00f3 C, Turner PE, Buckling A (2022) Mitigation of evolved bacterial resistance to phage therapy. Curr Opin Virol 53:101201. https:\/\/doi.org\/10.1016\/j.coviro.2022.101201","journal-title":"Curr Opin Virol"},{"key":"700_CR101","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03431-20","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, Smith BE, Garlena RA et al (2021) Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. Micro biol. https:\/\/doi.org\/10.1128\/mbio.03431-20","journal-title":"Micro biol"},{"key":"700_CR102","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam S, Courtwright AM, Koval C et al (2019) Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 19:2631\u20132639. https:\/\/doi.org\/10.1111\/ajt.15503","journal-title":"Am J Transplant"},{"key":"700_CR103","doi-asserted-by":"publisher","first-page":"758392","DOI":"10.3389\/fcimb.2021.758392","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Xie Z, Zhao J et al (2021) Prospects of inhaled phage therapy for combatting pulmonary infections. Front Cell Infect Microbiol 11:758392. https:\/\/doi.org\/10.3389\/fcimb.2021.758392","journal-title":"Front Cell Infect Microbiol"},{"key":"700_CR104","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejpb.2018.01.010","volume":"125","author":"A Astudillo","year":"2018","unstructured":"Astudillo A, Leung SSY, Kutter E et al (2018) Nebulization effects on structural stability of bacteriophage PEV 44. Eur J Pharm Biopharm 125:124\u2013130. https:\/\/doi.org\/10.1016\/j.ejpb.2018.01.010","journal-title":"Eur J Pharm Biopharm"},{"key":"700_CR105","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick RM, Freeman KG, Nguyen JA et al (2021) Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med 27:1357\u20131361. https:\/\/doi.org\/10.1038\/s41591-021-01403-9","journal-title":"Nat Med"},{"key":"700_CR106","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG (2023) CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402:1171\u20131184. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4","journal-title":"Lancet"},{"key":"700_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae051","author":"EL Ledger","year":"2024","unstructured":"Ledger EL, Smith DJ, Teh JJ et al (2024) Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis. J Infect Dis. https:\/\/doi.org\/10.1093\/infdis\/jiae051","journal-title":"J Infect Dis"},{"key":"700_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957","author":"DP Nichols","year":"2023","unstructured":"Nichols DP, Morgan SJ, Skalland M et al (2023) Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density but lung infections generally persist. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI167957","journal-title":"J Clin Invest"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00700-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T18:31:57Z","timestamp":1717180317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00700-7","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}